JP2017507130A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017507130A5 JP2017507130A5 JP2016550546A JP2016550546A JP2017507130A5 JP 2017507130 A5 JP2017507130 A5 JP 2017507130A5 JP 2016550546 A JP2016550546 A JP 2016550546A JP 2016550546 A JP2016550546 A JP 2016550546A JP 2017507130 A5 JP2017507130 A5 JP 2017507130A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- polymorphism
- patient
- seq
- snp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 28
- 239000003814 drug Substances 0.000 claims 19
- 239000000523 sample Substances 0.000 claims 17
- 108700028369 Alleles Proteins 0.000 claims 15
- 208000024827 Alzheimer disease Diseases 0.000 claims 12
- 239000002773 nucleotide Substances 0.000 claims 10
- 125000003729 nucleotide group Chemical group 0.000 claims 10
- 102000003780 Clusterin Human genes 0.000 claims 9
- 108090000197 Clusterin Proteins 0.000 claims 9
- 238000012408 PCR amplification Methods 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 230000003321 amplification Effects 0.000 claims 4
- 238000003556 assay Methods 0.000 claims 4
- 238000001514 detection method Methods 0.000 claims 4
- 238000003205 genotyping method Methods 0.000 claims 4
- 239000002122 magnetic nanoparticle Substances 0.000 claims 4
- 238000003199 nucleic acid amplification method Methods 0.000 claims 4
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 claims 4
- 102210009350 rs1532278 Human genes 0.000 claims 4
- 108091034117 Oligonucleotide Proteins 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 238000009396 hybridization Methods 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 2
- 108010060159 Apolipoprotein E4 Proteins 0.000 claims 2
- 238000001712 DNA sequencing Methods 0.000 claims 2
- 238000009015 Human TaqMan MicroRNA Assay kit Methods 0.000 claims 2
- 101710163270 Nuclease Proteins 0.000 claims 2
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims 2
- 238000007844 allele-specific PCR Methods 0.000 claims 2
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 claims 2
- 238000004458 analytical method Methods 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 210000001124 body fluid Anatomy 0.000 claims 2
- 239000010839 body fluid Substances 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 238000003935 denaturing gradient gel electrophoresis Methods 0.000 claims 2
- 238000003795 desorption Methods 0.000 claims 2
- 238000001962 electrophoresis Methods 0.000 claims 2
- 238000009585 enzyme analysis Methods 0.000 claims 2
- 238000004949 mass spectrometry Methods 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 2
- 238000003752 polymerase chain reaction Methods 0.000 claims 2
- 238000012175 pyrosequencing Methods 0.000 claims 2
- 108091008146 restriction endonucleases Proteins 0.000 claims 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 claims 2
- 210000003296 saliva Anatomy 0.000 claims 2
- 238000012163 sequencing technique Methods 0.000 claims 2
- 230000002123 temporal effect Effects 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 229950001863 bapineuzumab Drugs 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 229950002508 gantenerumab Drugs 0.000 claims 1
- 102000054765 polymorphisms of proteins Human genes 0.000 claims 1
- 229950007874 solanezumab Drugs 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461937472P | 2014-02-08 | 2014-02-08 | |
| US61/937,472 | 2014-02-08 | ||
| US201461971499P | 2014-03-27 | 2014-03-27 | |
| US61/971,499 | 2014-03-27 | ||
| US201462010265P | 2014-06-10 | 2014-06-10 | |
| US62/010,265 | 2014-06-10 | ||
| US201462082013P | 2014-11-19 | 2014-11-19 | |
| US62/082,013 | 2014-11-19 | ||
| PCT/US2015/014829 WO2015120280A1 (en) | 2014-02-08 | 2015-02-06 | Methods of treating alzheimer's disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019230686A Division JP2020090497A (ja) | 2014-02-08 | 2019-12-20 | アルツハイマー病を治療する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017507130A JP2017507130A (ja) | 2017-03-16 |
| JP2017507130A5 true JP2017507130A5 (OSRAM) | 2018-03-22 |
| JP6702878B2 JP6702878B2 (ja) | 2020-06-03 |
Family
ID=52574436
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016550546A Active JP6702878B2 (ja) | 2014-02-08 | 2015-02-06 | アルツハイマー病を治療する方法 |
| JP2019230686A Withdrawn JP2020090497A (ja) | 2014-02-08 | 2019-12-20 | アルツハイマー病を治療する方法 |
| JP2021181553A Pending JP2022036946A (ja) | 2014-02-08 | 2021-11-08 | アルツハイマー病を治療する方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019230686A Withdrawn JP2020090497A (ja) | 2014-02-08 | 2019-12-20 | アルツハイマー病を治療する方法 |
| JP2021181553A Pending JP2022036946A (ja) | 2014-02-08 | 2021-11-08 | アルツハイマー病を治療する方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20170369559A9 (OSRAM) |
| EP (2) | EP3102230B1 (OSRAM) |
| JP (3) | JP6702878B2 (OSRAM) |
| KR (1) | KR102476641B1 (OSRAM) |
| CN (2) | CN106456729A (OSRAM) |
| AU (2) | AU2015213741B2 (OSRAM) |
| BR (1) | BR112016018205A8 (OSRAM) |
| CA (1) | CA2938731A1 (OSRAM) |
| ES (1) | ES2873248T3 (OSRAM) |
| IL (1) | IL247085B (OSRAM) |
| MX (2) | MX388168B (OSRAM) |
| PL (1) | PL3102230T3 (OSRAM) |
| RU (2) | RU2020111676A (OSRAM) |
| SG (2) | SG11201606490YA (OSRAM) |
| TW (3) | TWI769970B (OSRAM) |
| WO (1) | WO2015120280A1 (OSRAM) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6205362B2 (ja) | 2011-09-08 | 2017-09-27 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性のステロイド、組成物、およびそれらの使用 |
| SMT201800657T1 (it) | 2013-03-13 | 2019-01-11 | Sage Therapeutics Inc | Steroidi neuroattivi e loro metodi di utilizzo |
| SMT202100226T1 (it) | 2015-07-06 | 2021-05-07 | Sage Therapeutics Inc | Ossisteroli e metodi di uso degli stessi |
| US10779762B2 (en) * | 2015-10-20 | 2020-09-22 | Washington University | MRI method for in vivo detection of amyloid and pathology in the Alzheimer brain |
| JP2019501115A (ja) * | 2015-10-28 | 2019-01-17 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 遺伝子治療のためのアデノ随伴ウイルスベクターのくも膜下腔内投与 |
| EP3405489A1 (en) * | 2016-01-20 | 2018-11-28 | Genentech, Inc. | High dose treatments for alzheimer's disease |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| TWI735600B (zh) | 2016-07-01 | 2021-08-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| WO2018023036A1 (en) * | 2016-07-29 | 2018-02-01 | Biogen Chesapeake Llc | Methods of treating or preventing amyloid related imaging abnormalities associated with alzheimer's disease treatment |
| ES3038660T3 (en) | 2016-10-18 | 2025-10-14 | Sage Therapeutics Inc | Oxysterols and methods of use thereof |
| JP2019020206A (ja) * | 2017-07-14 | 2019-02-07 | 株式会社島津製作所 | 質量分析を用いた認知機能障害疾患バイオマーカーの定量方法及び質量分析装置 |
| JP7368856B2 (ja) | 2017-07-25 | 2023-10-25 | トゥルーバインディング，インコーポレイテッド | Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療 |
| US11058729B2 (en) * | 2018-01-25 | 2021-07-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Exosomes and miRNA to treat glaucoma |
| CN116063505B (zh) | 2019-01-30 | 2024-05-03 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| KR102555878B1 (ko) * | 2020-04-23 | 2023-07-17 | 주식회사 바이오오케스트라 | 하향조절된 mirna의 진단 및 치료를 위한 용도 |
| KR102691806B1 (ko) * | 2020-04-23 | 2024-08-06 | 주식회사 바이오오케스트라 | 상향조절된 mirna의 진단 및 치료를 위한 용도 |
| AU2021273299A1 (en) * | 2020-05-14 | 2022-12-08 | The Hong Kong University Of Science And Technology | Protein markers for assessing alzheimer's disease |
| US12281166B2 (en) | 2020-05-26 | 2025-04-22 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking Galectin-3 |
| WO2022020680A1 (en) | 2020-07-23 | 2022-01-27 | Othair Prothena Limited | Anti-abeta antibodies |
| EP4248445A2 (en) * | 2020-11-19 | 2023-09-27 | Regeneron Pharmaceuticals, Inc. | Genotyping by sequencing |
| JP7731540B2 (ja) * | 2021-03-26 | 2025-09-01 | 国立研究開発法人農業・食品産業技術総合研究機構 | アミロイドβ蓄積リスクの有無の指標とする方法、一塩基多型（ＳＮＰ）の存在又は非存在を検出する方法、組成物、及びキット |
| JP2024520805A (ja) * | 2021-06-11 | 2024-05-24 | セージ セラピューティクス， インコーポレイテッド | アルツハイマー病の治療のための神経活性ステロイド |
| WO2024086796A1 (en) | 2022-10-20 | 2024-04-25 | Alector Llc | Anti-ms4a4a antibodies with amyloid-beta therapies |
| WO2024197258A1 (en) * | 2023-03-23 | 2024-09-26 | Klaritos, Inc | Methods of treating alzheimer's disease |
Family Cites Families (105)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US5202231A (en) | 1987-04-01 | 1993-04-13 | Drmanac Radoje T | Method of sequencing of genomes by hybridization of oligonucleotide probes |
| US5525464A (en) | 1987-04-01 | 1996-06-11 | Hyseq, Inc. | Method of sequencing by hybridization of oligonucleotide probes |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| JPH08500962A (ja) | 1992-02-06 | 1996-02-06 | クリエイティブ バイオモレキュルズ，インコーポレイテッド | 癌マーカー用生物合成結合蛋白質 |
| US5981176A (en) | 1992-06-17 | 1999-11-09 | City Of Hope | Method of detecting and discriminating between nucleic acid sequences |
| EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
| US6156501A (en) | 1993-10-26 | 2000-12-05 | Affymetrix, Inc. | Arrays of modified nucleic acid probes and methods of use |
| US6045996A (en) | 1993-10-26 | 2000-04-04 | Affymetrix, Inc. | Hybridization assays on oligonucleotide arrays |
| US5849483A (en) | 1994-07-28 | 1998-12-15 | Ig Laboratories, Inc. | High throughput screening method for sequences or genetic alterations in nucleic acids |
| US5589330A (en) | 1994-07-28 | 1996-12-31 | Genzyme Corporation | High-throughput screening method for sequence or genetic alterations in nucleic acids using elution and sequencing of complementary oligonucleotides |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US6239273B1 (en) | 1995-02-27 | 2001-05-29 | Affymetrix, Inc. | Printing molecular library arrays |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| US6152681A (en) | 1996-05-03 | 2000-11-28 | Arrowhead Systems, Llc | Container sweep for a palletizer and method |
| EP0866071B1 (en) | 1997-03-20 | 2004-10-20 | F. Hoffmann-La Roche Ag | Modified primers |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| ES2244066T3 (es) | 1997-06-24 | 2005-12-01 | Genentech, Inc. | Procedimiento y composiciones de glicoproteinas galactosiladas. |
| WO1999005574A1 (en) | 1997-07-25 | 1999-02-04 | Affymetrix, Inc. | Method and system for providing a probe array chip design database |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| CA2299625A1 (en) | 1997-08-15 | 1999-02-25 | Affymetrix, Inc. | Polymorphism detection utilizing clustering analysis |
| ATE419009T1 (de) | 1997-10-31 | 2009-01-15 | Genentech Inc | Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| ES2375931T3 (es) | 1997-12-05 | 2012-03-07 | The Scripps Research Institute | Humanización de anticuerpo murino. |
| DE69937291T2 (de) | 1998-04-02 | 2008-07-10 | Genentech, Inc., South San Francisco | Antikörpervarianten und fragmente davon |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| PT2180007E (pt) | 1998-04-20 | 2013-11-25 | Roche Glycart Ag | Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
| KR101155191B1 (ko) | 1999-01-15 | 2012-06-13 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6136541A (en) | 1999-02-22 | 2000-10-24 | Vialogy Corporation | Method and apparatus for analyzing hybridized biochip patterns using resonance interactions employing quantum expressor functions |
| ES2568899T3 (es) | 1999-04-09 | 2016-05-05 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de una molécula inmunofuncional |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| ES2248127T3 (es) | 1999-10-04 | 2006-03-16 | Medicago Inc. | Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno. |
| EP1257662A2 (en) | 1999-10-06 | 2002-11-20 | Amersham Biosciences Corp. | Method for detecting mutations using arrayed primer extension |
| US6709816B1 (en) | 1999-10-18 | 2004-03-23 | Affymetrix, Inc. | Identification of alleles |
| AU7950400A (en) | 1999-10-19 | 2001-04-30 | Kyowa Hakko Kogyo Co. Ltd. | Process for producing polypeptide |
| US20030180714A1 (en) | 1999-12-15 | 2003-09-25 | Genentech, Inc. | Shotgun scanning |
| SI2857516T1 (sl) | 2000-04-11 | 2017-09-29 | Genentech, Inc. | Multivalentna protitelesa in njihove uporabe |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| EP1331266B1 (en) | 2000-10-06 | 2017-01-04 | Kyowa Hakko Kirin Co., Ltd. | Cells producing antibody compositions |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| ES2405944T3 (es) | 2000-11-30 | 2013-06-04 | Medarex, Inc. | Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas |
| NZ603111A (en) | 2001-08-03 | 2014-05-30 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| ES2326964T3 (es) | 2001-10-25 | 2009-10-22 | Genentech, Inc. | Composiciones de glicoproteina. |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| US20050031613A1 (en) | 2002-04-09 | 2005-02-10 | Kazuyasu Nakamura | Therapeutic agent for patients having human FcgammaRIIIa |
| JPWO2003085119A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物のＦｃγ受容体ＩＩＩａに対する結合活性を高める方法 |
| BR0309145A (pt) | 2002-04-09 | 2005-02-01 | Kyowa Hakko Kogyo Kk | Células das quais o genoma é modificado |
| EP1500400A4 (en) | 2002-04-09 | 2006-10-11 | Kyowa Hakko Kogyo Kk | MEDICAMENT CONTAINING ANTIBODY COMPOSITION |
| AU2003236020B2 (en) | 2002-04-09 | 2009-03-19 | Kyowa Hakko Kirin Co., Ltd. | Cell with depression or deletion of the activity of protein participating in GDP-fucose transport |
| JPWO2003085118A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物の製造方法 |
| CA2488441C (en) | 2002-06-03 | 2015-01-27 | Genentech, Inc. | Synthetic antibody phage libraries |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| DE60332957D1 (de) | 2002-12-16 | 2010-07-22 | Genentech Inc | Immunoglobulinvarianten und deren verwendungen |
| WO2004065416A2 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| EP1688439A4 (en) | 2003-10-08 | 2007-12-19 | Kyowa Hakko Kogyo Kk | COMPOSITION OF CONDENSED PROTEINS |
| US20070134759A1 (en) | 2003-10-09 | 2007-06-14 | Harue Nishiya | Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase |
| JP4653109B2 (ja) | 2003-11-05 | 2011-03-16 | ロシュ グリクアート アクチェンゲゼルシャフト | 高められたＦｃレセプター結合親和性及びエフェクター機能をもつＣＤ２０抗体 |
| JPWO2005053742A1 (ja) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
| KR101245983B1 (ko) | 2004-03-31 | 2013-06-28 | 제넨테크, 인크. | 인간화 항-ｔｇｆ-베타 항체 |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| PL1737891T3 (pl) | 2004-04-13 | 2013-08-30 | Hoffmann La Roche | Przeciwciała przeciw selektynie p |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| TR201808537T4 (tr) | 2004-09-23 | 2018-07-23 | Genentech Inc | Sistein değiştirilmiş antikorlar ve konjugatlar. |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| US8679490B2 (en) | 2005-11-07 | 2014-03-25 | Genentech, Inc. | Binding polypeptides with diversified and consensus VH/VL hypervariable sequences |
| WO2007064919A2 (en) | 2005-12-02 | 2007-06-07 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| WO2007134050A2 (en) | 2006-05-09 | 2007-11-22 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
| KR101605207B1 (ko) * | 2006-07-14 | 2016-03-22 | 에이씨 이뮨 에스.에이. | 아밀로이드 베타에 대해 인간화된 항체 |
| ES2399075T3 (es) | 2006-08-30 | 2013-03-25 | Genentech, Inc. | Anticuerpos multiespecíficos |
| SI2074145T1 (sl) * | 2006-10-02 | 2017-12-29 | Ac Immune S.A. | Humanizirano protitelo proti amiloid beta |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| JO3076B1 (ar) * | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| WO2009089004A1 (en) | 2008-01-07 | 2009-07-16 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| ES2527653T3 (es) | 2008-10-20 | 2015-01-28 | F. Hoffmann-La Roche Ag | Amplificación específica de alelo usando un cebador con un nucleótido modificado |
| CN102229651A (zh) * | 2011-06-08 | 2011-11-02 | 中南大学 | 一种治疗阿尔茨海默病的淀粉样蛋白膜内片段及其应用 |
| GB201212334D0 (en) * | 2012-07-11 | 2012-08-22 | Warwick The | Therapeutic targets for alzheimers disease |
-
2015
- 2015-02-06 EP EP15706100.3A patent/EP3102230B1/en active Active
- 2015-02-06 CA CA2938731A patent/CA2938731A1/en active Pending
- 2015-02-06 KR KR1020167024494A patent/KR102476641B1/ko active Active
- 2015-02-06 WO PCT/US2015/014829 patent/WO2015120280A1/en not_active Ceased
- 2015-02-06 JP JP2016550546A patent/JP6702878B2/ja active Active
- 2015-02-06 SG SG11201606490YA patent/SG11201606490YA/en unknown
- 2015-02-06 EP EP21162693.2A patent/EP3900738A1/en not_active Withdrawn
- 2015-02-06 CN CN201580018454.4A patent/CN106456729A/zh active Pending
- 2015-02-06 RU RU2020111676A patent/RU2020111676A/ru unknown
- 2015-02-06 TW TW104104200A patent/TWI769970B/zh active
- 2015-02-06 MX MX2016010237A patent/MX388168B/es unknown
- 2015-02-06 PL PL15706100T patent/PL3102230T3/pl unknown
- 2015-02-06 TW TW111100089A patent/TW202239429A/zh unknown
- 2015-02-06 CN CN202110043649.1A patent/CN112826930A/zh active Pending
- 2015-02-06 RU RU2016132162A patent/RU2720468C2/ru active
- 2015-02-06 SG SG10201901076WA patent/SG10201901076WA/en unknown
- 2015-02-06 BR BR112016018205A patent/BR112016018205A8/pt not_active Application Discontinuation
- 2015-02-06 ES ES15706100T patent/ES2873248T3/es active Active
- 2015-02-06 TW TW110102168A patent/TWI785472B/zh active
- 2015-02-06 AU AU2015213741A patent/AU2015213741B2/en active Active
-
2016
- 2016-08-03 IL IL247085A patent/IL247085B/en active IP Right Grant
- 2016-08-05 MX MX2020010947A patent/MX2020010947A/es unknown
- 2016-08-17 US US15/239,225 patent/US20170369559A9/en not_active Abandoned
-
2019
- 2019-12-20 JP JP2019230686A patent/JP2020090497A/ja not_active Withdrawn
-
2020
- 2020-09-16 AU AU2020233696A patent/AU2020233696A1/en not_active Abandoned
-
2021
- 2021-05-26 US US17/330,898 patent/US20220098288A1/en not_active Abandoned
- 2021-11-08 JP JP2021181553A patent/JP2022036946A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017507130A5 (OSRAM) | ||
| CA2938731A1 (en) | Methods of treating alzheimer's disease | |
| AU2009313475B2 (en) | Genetic polymorphisms in age-related macular degeneration | |
| JP2020028293A5 (OSRAM) | ||
| EP2563939B1 (en) | Rapid genotyping analysis for human papillomavirus and the device thereof | |
| JP5676623B2 (ja) | 加齢黄斑変性における遺伝的多型性 | |
| JP2017513937A5 (OSRAM) | ||
| JP2010528590A5 (OSRAM) | ||
| RU2018122965A (ru) | Улучшенный способ и набор для определения тяжести и прогрессирования периодонтального заболевания | |
| JP6687532B2 (ja) | 神経変性疾患のミトコンドリアマーカー | |
| JP2013074888A (ja) | ＩＬ２８Ｂ（ｒｓ８０９９９１７）とＩＴＰＡ（ｒｓ１１２７３５４）の変異を検出する方法 | |
| KR101287431B1 (ko) | 표적 유전자의 다양한 변이가 존재하는 유전자 영역을 증폭하기 위한 프라이머 조성물, 이를 이용한 표적 유전자 증폭 방법 및 이를 포함하는 ｐｃｒ 증폭 키트 그리고 이를 이용한 표적 유전자의 유전자형 분석방법 | |
| CN102057055B (zh) | 分支杆菌的快速检测 | |
| US20070196849A1 (en) | Double-ligation Method for Haplotype and Large-scale Polymorphism Detection | |
| US20140371132A1 (en) | Codon signature for neuromyelitis optica | |
| Dwivedi et al. | Molecular biotechnology for diagnostics | |
| CN104789673A (zh) | rs1800818在检测新布尼亚病毒引起的发热伴血小板减少综合征中的应用 | |
| KR101598328B1 (ko) | Dna 복제수 변이를 이용한 강직성 척추염 발병 저위험도 예측용 조성물 및 이를 이용한 예측 방법 | |
| RU2695783C1 (ru) | Способ определения полиморфных маркеров в генах SLCO1B1, APOE и ABCB1 для определения индивидуальной чувствительности к статинам | |
| WO2011115033A1 (ja) | Ｃ型肝炎の治療効果を予測するためのマーカー群、検査方法及び検査用キット | |
| RU2556808C2 (ru) | СПОСОБ ОПРЕДЕЛЕНИЯ ГЕНОТИПА ЧЕЛОВЕКА ПО ПОЛИМОРФНОЙ ПОЗИЦИИ rs1613662 В ГЕНЕ GP6, КОДИРУЮЩЕМ ГЛИКОПРОТЕИН VI | |
| WO2006033384A1 (ja) | 放射線治療における副作用発症予測用ｄｎａオリゴマー、遺伝子マーカー、ｄｎａオリゴマーセット、および副作用発症予測方法 | |
| KR20160134094A (ko) | 펩티드핵산을 이용한 항체 의존성 세포 독성에 관여하는 항체 Fc 감마 리셉터의 유전자형 판별방법 | |
| HK1173192B (en) | Genetic polymorphisms in age-related macular degeneration | |
| HK1173192A (en) | Genetic polymorphisms in age-related macular degeneration |